Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy

Bibliography

• BerisP, Georgiou G. Overview of myelodysplastic syndromes. Semin Hematol 2012;49:287-94
   Google Scholar
• Neukirchen J, Schoonen WM, Strupp C, et al. Incidence and prevalence of myelodysplastic syndromes: data from the dusseldorf MDS-registry. Leuk Res 2011;35:1591-6
   PubMed Web of Science ®Google Scholar
• Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007;109:1536-42
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau M M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-65
   PubMed Web of Science ®Google Scholar
• Fenaux P, Ades L. How we treat lower-risk myelodysplastic syndromes. Blood 2013;23:4280-6
   Google Scholar
• Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European leukemianet. Blood 2013;122:2943-64
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012;87:692-701
   PubMed Web of Science ®Google Scholar
• Gyurkocza B, Deeg HJ. Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how? Blood Rev 2012;26:247-54
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Alessandrino EP, Bacigalupo A, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood 2014;123:2333-42
   PubMed Web of Science ®Google Scholar
• Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 2011;117:7121-5
   PubMed Web of Science ®Google Scholar
• Visser O, Trama A, Maynadiè M, et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012;48:3257-66
   PubMed Web of Science ®Google Scholar
• Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am 2010;24:287-94
   PubMed Web of Science ®Google Scholar
• Ma X. Epidemiology of myelodysplastic syndromes. Am J Med 2012;125:S2-5
   PubMed Web of Science ®Google Scholar
• Germing U, Aul C, Niemeyer CM, et al. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 2008;87:691-9
   PubMed Web of Science ®Google Scholar
• Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52
   PubMed Web of Science ®Google Scholar
• Pandolfi A, Barreyro L, Steidl U. Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells. Stem Cells Transl Med 2013;2(2):143-50
   PubMed Web of Science ®Google Scholar
• Jan M, Snyder TM, Corces-Zimmerman MR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012;29:149ra118
   Google Scholar
• Sand KE, Rye KP, Mannsåker B, et al. Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients. Oncoimmunology 2013;2:e23138
   Google Scholar
• Hirai H. Molecular mechanisms of myelodysplastic syndrome. Jpn J Clin Oncol 2003;33:153-60
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Mohamedali AM, Mufti GJ. Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes. Br J Haematol 2013;162:587-605
   PubMed Web of Science ®Google Scholar
• Graubert T, Walter MJ. Genetics of myelodyspalstic syndromes: new insights. Hematology Am Soc Hematol Educ Program 2011;2011:543-9
   PubMedGoogle Scholar
• Quesnel B, Fenaux P. p15INK4b gene methylation and myelodysplastic syndromes. Leuk Lymphoma 1999;35:437-43
   PubMed Web of Science ®Google Scholar
• Rosu-Myles M, Wolff L. p15Inkb: dual function in myelopoiesis and inactivation in myeloid disease. Blood Cells Mol Dis 2008;40:406-9
   Google Scholar
• Kim M, Oh B, Kim SY, et al. p15INK4b correlates with thrombocytopenia, blast percentage, and survival in myelodysplastic syndromes in a dose dependent manner: quantitation using pyrosequencing study. Leuk Res 2010;34:718-22
   Google Scholar
• Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012;119:3211-18
   PubMed Web of Science ®Google Scholar
• Taskesen E, Havermans M, van Lom K, et al. Two splice factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. Blood 2014;123(21):3327-35
   Google Scholar
• Kulasekararaj AG, Mohamedali AM, Mufti GJ. Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes. Br J Haematol 2013;162:587-605
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Smith AE, Mian SA, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5 and correlate with adverse prognosis. Br J Haematology 2013;160:660-72
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndrome and low blast count acute myeloid leukemia. Leukemia 2011;25:1147-52
   PubMed Web of Science ®Google Scholar
• Lin TL, Nagata Y, Kao HW, et al. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations. Haematologica 2014;99:28-36
   Google Scholar
• Graubert T, Walter MJ. Genetics of myelodysplastic syndromes: new insights. Hematology Am Soc Hematol Educ Program 2011;2011:543-9
   PubMedGoogle Scholar
• Vogler W, Miller D, Keller J. 5-Azacitidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia. Blood 1976;48:331-7
   PubMed Web of Science ®Google Scholar
• Leone G, Teofili L, Voso M, Lubbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002;87:1324-41
   PubMed Web of Science ®Google Scholar
• Hagemann S, Heil O, Lyko F, et al. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer dell lines. PLoS One 2011;6:e17388
   PubMed Web of Science ®Google Scholar
• Hollenbach P, Nguyen A, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. Plos One 2010;5:e9001
   PubMed Web of Science ®Google Scholar
• Marcucci G, Silverman L, Eller M, et al. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 2005;45:597-602
   PubMed Web of Science ®Google Scholar
• Lyons RM, Cosgriff TM, Modi SS, et al. Haematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009;27:1850-6
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G. Improving survival in myelodisplastic syndromes. Lancet Oncol 2009;10:200-1
   Google Scholar
• Haq B, Rossetti J, Kramer W, et al. Response and tolerability of a 5-day azacytidine schedule in patients with myelodysplastic syndromes. J Clin Oncol 2006;24:abstr 16532
   Google Scholar
• Chitambar CR, Libnoch JA, Mathaeus WG, et al. Evaluation of continuous infusion low- dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am J Hematol 1991;37:100-4
   PubMed Web of Science ®Google Scholar
• Silverman LR, Holland JF, Weimberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993(Suppl 1):21-9
   Google Scholar
• Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer AND Leukemia Group B. J Clin Oncol 2006;24:3895-903
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson AB, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-40
   PubMed Web of Science ®Google Scholar
• Kornblith AB, Herndon JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002;20:2441-52
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32
   PubMed Web of Science ®Google Scholar
• Fenaux P, Seymour JF, Santini V, et al. Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA001 myelodysplasia study model. Leuk Res 2014;38:258-62
   Google Scholar
• Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. Oncol Hematol 2010;76:218-27
   PubMed Web of Science ®Google Scholar
• Breccia M, Loglisci G, Salaroli A, et al. 5-azacitidine efficacy and safety in patients aged>65 years with myelodysplastic syndromes outside clinical trials. Leuk Lymphoma 2012;53:1558-60
   PubMed Web of Science ®Google Scholar
• Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403-11
   PubMed Web of Science ®Google Scholar
• Xicoy B, Jimenez MJ, Garcia O, et al. Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes. Leuk Lymphoma 2014;55:1300-6
   PubMed Web of Science ®Google Scholar
• van der Helm LH, Alhan C, Wijermans PW, et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes 8MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol 2011;155:599-606
   PubMed Web of Science ®Google Scholar
• Ozbalak M, Cetiner M, Bekoz H, et al. Azacitidine has limited activity in ‘real life’ patients with MDS and AML: a single centre experience. Hematol Oncol 2012;30:76-81
   PubMed Web of Science ®Google Scholar
• Naqvi K, Garcia-Manero G, Sardesai S, et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol 2011;29:2240-6
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011;96:441-9
   PubMed Web of Science ®Google Scholar
• Breccia M, Salaroli A, Loglisci G, et al. MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine. Haematologica 2012;97:e2
   Google Scholar
• Wang R, Gross CP, Frick K, et al. The impact of hypomethilating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leuk Res 2012;36:1370-5
   PubMed Web of Science ®Google Scholar
• Crespo C, Moreno E, Sierra J, et al. Cost-effectiveness analysis of aacitidine in the treatment of high-risk myelodysplastic syndromes in Spain. Health Econ Rev 2013;3:28
   PubMedGoogle Scholar
• Levy AR, Zou D, Risebrough N, et al. Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes. Curr Oncol 2014;21:e29-40
   PubMed Web of Science ®Google Scholar